Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors

Eisai Celebrates Launch of new Belgium Operation


First drug reimbursement submission for new office is Halaven®(eribulin), a novel treatment for advanced breast cancer

HATFIELD, England, September 16, 2013 /PRNewswire/ — Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of one of the world’s leading research and development (R&D) based pharmaceutical companies, has opened a new business operation in Belgium with an office based in Brussels.

The Belgium office will be responsible for marketing Eisai’s Inovelon® (rufinamide), indicated as an adjunctive therapy in the treatment of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) in patients 4 years and older,[1] which has been commercially available in Belgium since March 2012. Rufinamide was granted orphan drug status for adjunctive treatment of patients with this particularly hard-to-treat syndrome in October 2004.

Eisai has submitted Halaven® (eribulin), an innovative metastatic breast cancer (MBC) treatment, for local reimbursement approval by INAMI/RIZIV in Belgium. Eribulin received European Commission approval in March 2011 and is indicated for the treatment of patients with locally advanced or MBC who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless women were not suitable for these treatments.[2]

Commenting on the submission of eribulin for reimbursement approval in Belgium, Nicolas Kormoss, M.D., Medical Director for Belgium and Luxemburg, Eisai EMEA said: «Belgium has one of the highest rates of breast cancer in the world, with around 2,500 women dying from breast cancer every year. We hope the local health authorities recognise the clinical value that Halaven could bring to those in the country with advanced breast cancer.«[3]

The Belgium office opening comes as part of Eisai’s globalisation strategy set out in its mid-term strategic plan in 2011 «HAYABUSA», in which the company seeks to expand its global presence by 2015 in an effort to achieve its objective to make contributions to more than 500 million patients worldwide.

Commenting on the opening of the new Belgium office Gary Hendler, President and CEO, Eisai EMEA said: «We are delighted to open an Eisai office in such a key European market, both to support Inovelon and to provide a solid base for the launch of Halaven in the future.»

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with cancer and epilepsy, and their families. The continued development of its oncology and epilepsy portfolios underscores Eisai’s human health care mission, the company’s commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide.

Source: firstwordpharma.com

Back to the list

Invite partners to the exhibition
Facebook Youtube RSS Feed

Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34